Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paulus S Rommer

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Autoimmunity Reviews|February 17, 2020
Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic reviewJohann Sellner, Paulus S Rommer
Current Treatment Options in Neurology|April 24, 2013
Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspectsPaulus S Rommer, Olaf Stüve
Vaccines|February 2, 2021
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting TherapiesJohann Sellner, Paulus S Rommer
Current Pharmaceutical Design|June 27, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part II: Autoimmunity Beyond the CNS and Other DisordersPaulus S Rommer, Uwe K Zettl
Expert Opinion on Pharmacotherapy|March 13, 2018
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patientsPaulus S Rommer, Uwe K Zettl
Nature Reviews. Neurology|July 26, 2023
New consensus guidelines on vaccination in multiple sclerosisUwe K Zettl, Paulus S Rommer
Current Pharmaceutical Design|April 5, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNSPaulus S Rommer, Uwe K Zettl
The Lancet. Neurology|May 21, 2018
Applying the 2017 McDonald diagnostic criteria for multiple sclerosisPaulus S Rommer, Uwe K Zettl
Current Opinion in Neurology|May 7, 2020
Prevention and management of adverse effects of disease modifying treatments in multiple sclerosisLucia Moiola, Paulus S Rommer, Uwe K Zettl
Current Pharmaceutical Design|May 23, 2012
Monoclonal antibodies in the treatment of neuroimmunological diseasesPaulus S Rommer, Robert Patejdl, Uwe K Zettl
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Autoimmunity Reviews|February 17, 2020
Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic reviewJohann Sellner, Paulus S Rommer
Current Treatment Options in Neurology|April 24, 2013
Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspectsPaulus S Rommer, Olaf Stüve
Vaccines|February 2, 2021
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting TherapiesJohann Sellner, Paulus S Rommer
Current Pharmaceutical Design|June 27, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part II: Autoimmunity Beyond the CNS and Other DisordersPaulus S Rommer, Uwe K Zettl
Expert Opinion on Pharmacotherapy|March 13, 2018
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patientsPaulus S Rommer, Uwe K Zettl
Nature Reviews. Neurology|July 26, 2023
New consensus guidelines on vaccination in multiple sclerosisUwe K Zettl, Paulus S Rommer
Current Pharmaceutical Design|April 5, 2022
Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNSPaulus S Rommer, Uwe K Zettl
The Lancet. Neurology|May 21, 2018
Applying the 2017 McDonald diagnostic criteria for multiple sclerosisPaulus S Rommer, Uwe K Zettl
Current Opinion in Neurology|May 7, 2020
Prevention and management of adverse effects of disease modifying treatments in multiple sclerosisLucia Moiola, Paulus S Rommer, Uwe K Zettl
Current Pharmaceutical Design|May 23, 2012
Monoclonal antibodies in the treatment of neuroimmunological diseasesPaulus S Rommer, Robert Patejdl, Uwe K Zettl
Pageof 8